mozavaptan has been researched along with Carcinoma, Small Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeuchi, K; Tamura, T | 1 |
| Iguchi, H; Kawahara, M; Kodama, T; Kuriyama, T; Mori, K; Sakurai, M; Shijubo, N; Shinkai, T; Sugiura, T; Yamaguchi, K | 1 |
1 trial(s) available for mozavaptan and Carcinoma, Small Cell
| Article | Year |
|---|---|
Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Antineoplastic Agents; Benzamides; Benzazepines; Biomarkers; Carcinoma, Small Cell; Female; Humans; Inappropriate ADH Syndrome; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Sodium; Thymus Neoplasms; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
1 other study(ies) available for mozavaptan and Carcinoma, Small Cell
| Article | Year |
|---|---|
Small cell gall bladder carcinoma complicated by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) treated with mozavaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Antimetabolites, Antineoplastic; Benzazepines; Carcinoma, Small Cell; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Inappropriate ADH Syndrome; Middle Aged; Treatment Outcome | 2013 |